Eloxx Pharmaceuticals (ELOX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends ELOX vs. ALVO, GNCAQ, VECT, AMGN, GILD, ARGX, BNTX, BIIB, MRNA, and NBIXShould you be buying Eloxx Pharmaceuticals stock or one of its competitors? The main competitors of Eloxx Pharmaceuticals include Alvotech (ALVO), Genocea Biosciences (GNCAQ), VectivBio (VECT), Amgen (AMGN), Gilead Sciences (GILD), argenx (ARGX), BioNTech (BNTX), Biogen (BIIB), Moderna (MRNA), and Neurocrine Biosciences (NBIX). These companies are all part of the "biological products, except diagnostic" industry. Eloxx Pharmaceuticals vs. Alvotech Genocea Biosciences VectivBio Amgen Gilead Sciences argenx BioNTech Biogen Moderna Neurocrine Biosciences Eloxx Pharmaceuticals (NASDAQ:ELOX) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings. Does the media prefer ELOX or ALVO? In the previous week, Alvotech's average media sentiment score of 1.00 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Alvotech is being referred to more favorably in the news media. Company Overall Sentiment Eloxx Pharmaceuticals Neutral Alvotech Positive Which has more risk and volatility, ELOX or ALVO? Eloxx Pharmaceuticals has a beta of 2.49, meaning that its share price is 149% more volatile than the S&P 500. Comparatively, Alvotech has a beta of -0.15, meaning that its share price is 115% less volatile than the S&P 500. Which has better earnings & valuation, ELOX or ALVO? Eloxx Pharmaceuticals has higher earnings, but lower revenue than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEloxx PharmaceuticalsN/AN/A-$36.06M-$9.07N/AAlvotech$391.87M9.16-$551.73M-$1.85-6.44 Do institutionals & insiders have more ownership in ELOX or ALVO? 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 0.5% of Alvotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ELOX or ALVO more profitable? Eloxx Pharmaceuticals has a net margin of 0.00% compared to Alvotech's net margin of -123.47%. Company Net Margins Return on Equity Return on Assets Eloxx PharmaceuticalsN/A N/A N/A Alvotech -123.47%N/A -35.87% Do analysts prefer ELOX or ALVO? Alvotech has a consensus target price of $18.00, suggesting a potential upside of 51.13%. Given Alvotech's stronger consensus rating and higher possible upside, analysts clearly believe Alvotech is more favorable than Eloxx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eloxx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alvotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ELOX or ALVO? Eloxx Pharmaceuticals received 7 more outperform votes than Alvotech when rated by MarketBeat users. However, 46.15% of users gave Alvotech an outperform vote while only 43.33% of users gave Eloxx Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEloxx PharmaceuticalsOutperform Votes1343.33% Underperform Votes1756.67% AlvotechOutperform Votes646.15% Underperform Votes753.85% SummaryEloxx Pharmaceuticals beats Alvotech on 8 of the 15 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Eloxx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELOX vs. The Competition Export to ExcelMetricEloxx PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio0.0046.7390.0517.18Price / SalesN/A415.011,116.25117.05Price / CashN/A182.1043.1037.85Price / BookN/A3.894.784.78Net Income-$36.06M-$42.21M$120.31M$225.60M Eloxx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELOXEloxx PharmaceuticalsN/AN/AN/AN/A$0.00N/A0.0018ALVOAlvotech2.6676 of 5 stars$11.28-1.1%$18.00+59.6%+6.9%$0.00$93.38M0.001,026GNCAQGenocea BiosciencesN/AN/AN/AN/A$0.00$1.64M0.0070VECTVectivBioN/A$16.85flatN/AN/A$0.00$27.34M0.0030AMGNAmgen4.4625 of 5 stars$277.63+1.9%$323.05+16.4%-5.7%$149.23B$28.19B34.9026,700Analyst DowngradeGap UpGILDGilead Sciences4.4195 of 5 stars$90.59-1.7%$95.41+5.3%+17.3%$112.90B$27.12B1,023.6718,000Insider TradeARGXargenx3.0031 of 5 stars$611.01-1.9%$635.42+4.0%+76.2%$36.89B$1.27B0.001,148Analyst ForecastShort Interest ↓Positive NewsBNTXBioNTech2.027 of 5 stars$120.82-0.7%$138.67+14.8%+9.2%$28.72B$4.13B-57.056,133BIIBBiogen4.6279 of 5 stars$156.46-0.8%$253.08+61.8%-42.3%$22.80B$9.84B14.257,570Analyst DowngradeMRNAModerna4.2751 of 5 stars$45.65+2.7%$83.33+82.5%-56.8%$17.10B$5.06B-7.845,600Analyst DowngradeNBIXNeurocrine Biosciences4.8318 of 5 stars$129.12+0.8%$163.91+26.9%+11.8%$13.07B$1.89B34.351,400Analyst ForecastInsider Trade Related Companies and Tools Related Companies Alvotech Competitors Genocea Biosciences Competitors VectivBio Competitors Amgen Competitors Gilead Sciences Competitors argenx Competitors BioNTech Competitors Biogen Competitors Moderna Competitors Neurocrine Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELOX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
